Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-137012

Published: 2020

Journal Articles

Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q

Cecile Bally, Raphael Itzykson, MD, Berangere Gruson, MD, Dreyfus Francois, Virginie Siguret, Anne-Laure Taksin, Benoit de Renzis, Laurence Legros, Xavier Thomas, MD, PhD, Krimo Bouabdallah, MD, Pascal Chaibi, MD, Charikleia Kelaidi, Pierre Fenaux, MD, PhD, Lionel Ades

Blood (2011) 118 (21): 2786.

https://doi.org/10.1182/blood.V118.21.2786.2786

Published: 2011

Journal Articles

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Blood (2011) 117 (2): 403–411.

https://doi.org/10.1182/blood-2010-06-289280

Published: 2011

Journal Articles

A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial

Blood (2010) 116 (21): 3996.

https://doi.org/10.1182/blood.V116.21.3996.3996

Published: 2010

Journal Articles

Azacytidine (AZA) in MDS (including RAEB-t and CMML) in Patients (pts) ≥ 80 Years: Results of the French ATU Program.

Raphael Itzykson, Sylvain Thépot, Bechir Achour, Bruno Quesnel, Francois Dreyfus, MD, PhD, Pascal Turlure, MD, Anne-Laure Taksin, MD, Norbert Vey, MD, Anne Marfaing Koka, Stephane de Botton, MD, PhD, Eric Wattel, MD, PhD, Francoise Isnard, Isabelle Plantier, Caroline Dartigeas, Chahinez Zerhouni, Claude Gardin, Lionel Ades, MD, Odile Beyne-Rauzy, MD, PhD, Pierre Fenaux

Blood (2009) 114 (22): 1773.

https://doi.org/10.1182/blood.V114.22.1773.1773

Published: 2009

Journal Articles

Prognostic Factors of Response and Overall Survival (OS) in Higher-Risk MDS (including RAEB-t) Treated with Azacytidine (AZA): Results of the French ATU Program.

Blood (2009) 114 (22): 3820.

https://doi.org/10.1182/blood.V114.22.3820.3820

Published: 2009

Journal Articles

Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.

Blood (2009) 114 (22): 843.

https://doi.org/10.1182/blood.V114.22.843.843

Published: 2009

Journal Articles

A Phase II Study of Post–Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study.

Claude Gardin, MD, Thomas Prébet, MD, Krimo Bouabdallah, MD, Denis Caillot, MD, Agnès Guerci, MD, PhD, Emmanuel Raffoux, MD, Jean Pierre Marolleau, MD, Cecile Pautas, MD, Anne Banos, MD, Chantal Himberlin, MD, Anne-Laure Taksin, MD, Arnaud Pigneux, MD, PhD, Xavier Thomas, MD, PhD, Tony Jernival, Norbert Vey, Francois Dreyfus, MD, PhD, Sylvie Chevret, PhD, Herve Dombret, MD, PhD, Pierre Fenaux

Blood (2009) 114 (22): 844.

https://doi.org/10.1182/blood.V114.22.844.844

Published: 2009

Journal Articles

Characteristics and Outcome of MDS with Isolated Del 20q: The GFM Experience in 64 Cases.

Thorsten Braun, Stephane de Botton, Anne-Laure Taksin, Sophie Park, Odile Beyne-Rauzy, Sylvie Chevret, Michaela Fontenay, Bruno Cassinat, Anne Lazareth, Virginie Eclache, Chrisitine Terre, Norbert Vey, Agnes Guerci, Francois Dreyfus, Dominique Bordessoule, Aspasia Stamatoullas, Sylvie Castaigne, Pierre Fenaux, Lionel Ades

Blood (2008) 112 (11): 1657.

https://doi.org/10.1182/blood.V112.11.1657.1657

Published: 2008

Journal Articles

Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM

Blood (2008) 112 (11): 2672.

https://doi.org/10.1182/blood.V112.11.2672.2672

Published: 2008

Journal Articles

Incidence of Disease Transformation and Development of MDS/AML in 165 Patients with Waldenström’s Macroglobulinemia (WM) Treated with Fludarabine (F)-Based Regimen in Three Studies (French Cooperative Group on CLL/WM)

Veronique Leblond, MD, Jerome Tamburini, MD, Vincent Levy, MD, PhD, Sylvain Choquet, MD, Anne Laure Taksin, MD, Frederic Maloisel, MD, Pierre Morel, MD

Blood (2007) 110 (11): 1291.

https://doi.org/10.1182/blood.V110.11.1291.1291

Published: 2007

Journal Articles

Autologous Hematopoietic Stem Cell Collection and Transplantation in Acute Myeloid Leukemia Patients in Second Remission after Treatment with Fractionated Gentuzumab Ozogamycin.

Delphine Rea, MD, PhD, Emmanuel Raffoux, MD, Anne Laure Taksin, MD, Adrienne De Labarthe, MD, Nicolas Boissel, MD, Jean Michel Miclea, MD, Sylvie Castaigne, MD, Herve Dombret, MD, PhD

Blood (2006) 108 (11): 5211.

https://doi.org/10.1182/blood.V108.11.5211.5211

Published: 2006

Journal Articles

Intensive Chemotherapy Followed by Hematopoietic Stem Cell Rescue for Refractory or Recurrent Primary Central Nervous System (PCNSL) or Intra Ocular Lymphoma (IOL). Results of a Multicentric Phase II Study.

Carole Soussain, MD, Khe Hoang-Xuan, MD, Luc Taillandier, MD, Olivier Casasnovas, MD, Brigitte Dupriez, MD, Anne-Laure Taksin, MD, Bertrand Souleau, MD, Brigitte Kolb, MD, Arnaud Jaccard, MD, Jean-Marc Zini, MD, Sylvain Choquet, MD, Francis Witz, MD, Maud Janvier, MD, Veronique Leblond, MD

Blood (2006) 108 (11): 402.

https://doi.org/10.1182/blood.V108.11.402.402

Published: 2006

Journal Articles

Fractionated Doses Mylotarg in First Relapsed AML Patients Is Effective and Safe: Results of a Prospective French Alfa Group Study.

Anne Laure Taksin, Emmanuel Raffoux, Thierry de Revel, Xavier Thomas, Nathalie Contentin, Reda Bouabdallah, Cecile Pautas, Dominique Bordessoulle, Olivier Legrand, Herve Dombret, Fadela Pousset, Sylvie Chevret, Sylvie Castaigne

Blood (2005) 106 (11): 1850.

https://doi.org/10.1182/blood.V106.11.1850.1850

Published: 2005

Journal Articles

Low Incidence of Hepatic Veno-Occlusive Disease after Fractionated Doses of Mylotarg and Autologous or Allogeneic Stem Cell Transplantation.

Hassan Farhat, Emmanuel Raffoux, Francoise Isnard, Nathalie Contentin, Anne Laure Taksin, Herve Dombret, Sylvie Castaigne, Philippe Rousselot

Blood (2005) 106 (11): 5300.

https://doi.org/10.1182/blood.V106.11.5300.5300

Published: 2005

Journal Articles

Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors

Stéphane Giraudier, Hédia Chagraoui, Emiko Komura, Stéphane Barnache, Benoit Blanchet, Jean Pierre LeCouedic, David F. Smith, Frédéric Larbret, Anne-Laure Taksin, Françoise Moreau-Gachelin, Nicole Casadevall, Michel Tulliez, Anne Hulin, Najet Debili, William Vainchenker

Blood (2002) 100 (8): 2932–2940.

https://doi.org/10.1182/blood-2002-02-0485

Published: 2002

Journal Articles

Autonomous Megakaryocyte Growth in Essential Thrombocythemia and Idiopathic Myelofibrosis Is Not Related to a c-mpl Mutation or to an Autocrine Stimulation by Mpl-L

Anne Laure Taksin, Jean-Pierre Le Couedic, Isabelle Dusanter-Fourt, Aline Massé, Stéphane Giraudier, André Katz, Françoise Wendling, William Vainchenker, Nicole Casadevall, Najet Debili

Blood (1999) 93 (1): 125–139.

https://doi.org/10.1182/blood.V93.1.125

Published: 1999

NARROW

Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS

Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial

Azacytidine (AZA) in MDS (including RAEB-t and CMML) in Patients (pts) ≥ 80 Years: Results of the French ATU Program.

Prognostic Factors of Response and Overall Survival (OS) in Higher-Risk MDS (including RAEB-t) Treated with Azacytidine (AZA): Results of the French ATU Program.

Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.

A Phase II Study of Post–Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study.

Characteristics and Outcome of MDS with Isolated Del 20q: The GFM Experience in 64 Cases.

Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM

Incidence of Disease Transformation and Development of MDS/AML in 165 Patients with Waldenström’s Macroglobulinemia (WM) Treated with Fludarabine (F)-Based Regimen in Three Studies (French Cooperative Group on CLL/WM)

Autologous Hematopoietic Stem Cell Collection and Transplantation in Acute Myeloid Leukemia Patients in Second Remission after Treatment with Fractionated Gentuzumab Ozogamycin.

Intensive Chemotherapy Followed by Hematopoietic Stem Cell Rescue for Refractory or Recurrent Primary Central Nervous System (PCNSL) or Intra Ocular Lymphoma (IOL). Results of a Multicentric Phase II Study.

Fractionated Doses Mylotarg in First Relapsed AML Patients Is Effective and Safe: Results of a Prospective French Alfa Group Study.

Low Incidence of Hepatic Veno-Occlusive Disease after Fractionated Doses of Mylotarg and Autologous or Allogeneic Stem Cell Transplantation.

Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors

Autonomous Megakaryocyte Growth in Essential Thrombocythemia and Idiopathic Myelofibrosis Is Not Related to a c-mpl Mutation or to an Autocrine Stimulation by Mpl-L

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only